CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 97 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $515,693,234 | -31.0% | 23,623,144 | +0.6% | 0.04% | -28.6% |
| Q2 2023 | $746,867,552 | -34.8% | 23,493,789 | -49.9% | 0.06% | +21.2% |
| Q1 2023 | $1,144,732,864 | +55.0% | 46,934,516 | +100.4% | 0.05% | -28.8% |
| Q4 2022 | $738,576,334 | +12.1% | 23,417,132 | +0.4% | 0.07% | +5.8% |
| Q3 2022 | $658,898,000 | +12.0% | 23,315,565 | +4.8% | 0.07% | +16.9% |
| Q2 2022 | $588,116,000 | -24.3% | 22,243,384 | +0.2% | 0.06% | -4.8% |
| Q1 2022 | $777,363,000 | +22.9% | 22,204,001 | +13.8% | 0.06% | +31.9% |
| Q4 2021 | $632,508,000 | +14.0% | 19,509,813 | +3.7% | 0.05% | +6.8% |
| Q3 2021 | $554,796,000 | +145.0% | 18,806,629 | +112.8% | 0.04% | +144.4% |
| Q2 2021 | $226,406,000 | +222.5% | 8,837,061 | +72.9% | 0.02% | +200.0% |
| Q1 2021 | $70,193,000 | -1.9% | 5,112,400 | +18.5% | 0.01% | 0.0% |
| Q4 2020 | $71,521,000 | – | 4,313,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |